Bonac Corporation (“Bonac”; HQ: Kurume City, Fukuoka; CEO: Hirotake Hayashi) is announced the conclusion of an exclusive license agreement with Sumitomo Chemical Co. Ltd. (Location: Chuo-ku, Tokyo; President: Masakazu Tokura) of intellectual property rights related to the manufacture and sale of bulk nucleic acid drugs.

 

Bonac will continue to promote research and development so that the nucleic acid technology will become a bridge to drug discovery.

 

Contact:

Corporate Affairs

press@bonac.co.jp